Related Experiment Video

Updated: Nov 12, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.3K

Paving the way to precision medicine in multiple myeloma

Shafqat Inam1, Jeremy A Ross2, Cyrille Touzeau3,4

  • 1Clinical haematology, Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Melbourne, Australia.

Expert Review of Hematology
|March 17, 2021
PubMed
Abstract

No abstract available in PubMed .

Keywords:
BCL2Venetoclaxapoptosismultiple myelomaprecision medicinetargeted therapy

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K

Related Experiment Videos

Last Updated: Nov 12, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.3K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K

Articles linked to this work by shared authors, journal, and citation graph.

Subtype specific artificial intelligence modelling of cardiac amyloidosis using echocardiography and electrocardiography.

European heart journal. Digital health·2026

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

American journal of hematology·2026

Bispecific Antibodies and T-Cell Engagers in Multiple Myeloma.

European journal of haematology·2026

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Leukemia·2026

Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results.

Blood·2026

Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study.

Blood·2026

Treatment of older adults with newly diagnosed FLT3-mutated AML: focus on lower-intensity triplet regimens.

Expert review of hematology·2026

Shear wave elastography as a screening modality for liver fibrosis in a comprehensive sickle cell disease clinic.

Expert review of hematology·2026

Nilotinib in chronic myeloid leukemia: clinical value, real-world challenges, and the potential of nilotinib tablets to improve therapeutic outcomes.

Expert review of hematology·2026

Infrastructure and workforce development processes inspired by Lived Experience Experts and grounded in health equity for the Bleeding Disorders Research Collaborative.

Expert review of hematology·2026

Research agenda and related workforce requirements inspired by Lived Experience Experts and grounded in health equity for the Bleeding Disorders Research Collaborative.

Expert review of hematology·2026

Bleeding Disorders Research Collaborative: an opportunity for impact.

Expert review of hematology·2026

Can Telehealth Improve Access to Amyloid-Targeting Therapies for Veterans Living With Alzheimer Disease?

Federal practitioner : for the health care professionals of the VA, DoD, and PHS·2026

Correction to: Sustained release microneedle patch for pronounced systemic delivery of doxazosin mesylate.

BioImpacts : BI·2026

A Nomogram Integrating Clinical and Cardiac Imaging for Predicting Short-Term Left Ventricular Ejection Fraction Decline in Patients with Duchenne Muscular Dystrophy.

International journal of general medicine·2026

Metformin modulates the phenotypes of tumor-associated macrophages in glioblastoma in a context-dependent manner by promoting the homeostasis of macrophages.

Frontiers in oncology·2026

OAF Blocks SIAH1-Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Real World Data and Its Impact on the Management of Plasma Cell Dyscrasias.

Current hematologic malignancy reports·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us